IGF-1R and ErbB3/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer model

Biochemical and Biophysical Research Communications

Volumn 436, Issue 4, 2013, Pages 740-745

  Jia, Yanhan ^a,b   Zhang, Yan ^c   Qiao, Chunxia ^b   Liu, Guijun ^b   Zhao, Qing ^b,c   Zhou, Tingting ^b   Chen, Guojiang ^b   Li, Yali ^c   Feng, Jiannan ^b   Li, Yan ^b   Zhang, Qiuping ^a   Peng, Hui ^b,d  

^a WUHAN UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d Institute of Health and Environmental Medicine   (China)

Author keywords

Drug resistance; ErbB3 HER3; IGF 1R; Ovarian cancer; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN RET; SHORT HAIRPIN RNA; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

DRUG RESISTANCE; ERBB3/HER3; IGF-1R; OVARIAN CANCER; TRASTUZUMAB;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; UP-REGULATION;

EID: 84880041531     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.030     Document Type: Article

References (26)

1. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
2. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu M.C., Sauter G., von Minckwitz G., Visco F., Bee V., Buyse M., Bendahmane B., Tabah-Fisch I., Lindsay M.A., Riva A., Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011, 365:1273-1283.
3. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
4. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
5. Zhang S., Huang W.C., Li P., Guo H., Poh S.B., Brady S.W., Xiong Y., Tseng L.M., Li S.H., Ding Z., Sahin A.A., Esteva F.J., Hortobagyi G.N., Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 2011, 17:461-469.
6. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
7. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J. Clin. Oncol. 2003, 21:283-290.
8. Wilken J.A., Webster K.T., Maihle N.J. Trastuzumab sensitizes ovarian cancer cells to egfr-targeted therapeutics. J. Ovarian Res. 2010, 3:7.
9. McAlpine J.N., Wiegand K.C., Vang R., Ronnett B.M., Adamiak A., Kobel M., Kalloger S.E., Swenerton K.D., Huntsman D.G., Gilks C.B., Miller D.M. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009, 9:433.
10. Steffensen K.D., Waldstrom M., Andersen R.F., Olsen D.A., Jeppesen U., Knudsen H.J., Brandslund I., Jakobsen A. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int. J. Oncol. 2008, 33:195-204.
11. Kulasingam V., Pavlou M.P., Diamandis E.P. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat. Rev. Cancer 2010, 10:371-378.
12. Bowtell D.D. The genesis and evolution of high-grade serous ovarian cancer. Nat. Rev. Cancer 2010, 10:803-808.
13. Luistro L.L., Rosinski J.A., Bian H., Bishayee S., Rameshwar P., Ponzio N.M., Ritland S.R. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab. Int. J. Oncol. 2012, 41:639-651.
14. Liu B., Fan Z., Edgerton S.M., Yang X., Lind S.E., Thor A.D. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 2011, 10:2959-2966.
15. Sims A.H., Zweemer A.J., Nagumo Y., Faratian D., Muir M., Dodds M., Um I., Kay C., Hasmann M., Harrison D.J., Langdon S.P. Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br. J. Cancer 2012, 106:1779-1789.
16. Peng H., Dong Z., Qi J., Yang Y., Liu Y., Li Z., Xu J., Zhang J.T. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS One 2009, 4:e5676.
17. Narayan M., Wilken J.A., Harris L.N., Baron A.T., Kimbler K.D., Maihle N.J. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res. 2009, 69:2191-2194.
18. Hellstrom I., Goodman G., Pullman J., Yang Y., Hellstrom K.E. Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 2001, 61:2420-2423.
19. Makhija S., Amler L.C., Glenn D., Ueland F.R., Gold M.A., Dizon D.S., Paton V., Lin C.Y., Januario T., Ng K., Strauss A., Kelsey S., Sliwkowski M.X., Matulonis U. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J. Clin. Oncol. 2010, 28:1215-1223.
20. Bezler M., Hengstler J.G., Ullrich A. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol. Oncol. 2012, 6:516-529.
21. An Y., Cai L., Wang Y., Zhu D., Guan Y., Zheng J. Local expression of insulin-like growth factor-I, insulin-like growth factor-I receptor, and estrogen receptor alpha in ovarian cancer. Onkologie 2009, 32:638-644.
22. Liu D., Liu J., Wang C., Lin B., Liu Q., Hao Y., Zhang S., Iwamori M. The stimulation of IGF-1R expression by lewis(y) antigen provides a powerful development mechanism of epithelial ovarian carcinoma. Int. J. Mol. Sci. 2011, 12:6781-6795.
23. Bruchim I., Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin. Ther. Targets 2013, 17:307-320.
24. Gotlieb W.H., Bruchim I., Gu J., Shi Y., Camirand A., Blouin M.J., Zhao Y., Pollak M.N. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol. 2006, 100:389-396.
25. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65:11118-11128.
26. Huang X., Gao L., Wang S., McManaman J.L., Thor A.D., Yang X., Esteva F.J., Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010, 70:1204-1214.